ACTIVAERO PROVIDES UPDATE ON Q4 2013 PARTNERING ACTIVITIES
Activaero GmbH /
ACTIVAERO PROVIDES UPDATE ON Q4 2013 PARTNERING ACTIVITIES
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* RESEARCH AGREEMENTS SIGNED WITH TWO LEADING PHARMACEUTICAL PLAYERS AND
IMPORTANT EUROPEAN SPECIALTY PHARMA COMPANY
* NEW DEVELOPMENT AND LICENSE AGREEMENT WITH PARION SCIENCES
Gemuenden/Wohra, Germany, January 10, 2014 - Activaero GmbH, the therapeutic
area specialist for respiratory diseases focusing on novel, pharmacoeconomically
meaningful treatment solutions for severe lung diseases, today provided an
update on its partnering activities in Q4 2013. Towards the end of the year, the
Company signed two research agreements, with one of the Top10 pharmaceutical
companies and with a major European Specialty Pharma company. In addition,
Activaero entered into a development collaboration with another Top20
pharmaceutical firm. Details of the agreements are not disclosed.
Finally, in October 2013, the respiratory area specialist has entered into a
development and license agreement with Parion Sciences Inc., a privately-held US
pharmaceutical company focusing on the discovery and development of pulmonary
and ophthalmology therapeutics. Under the terms of the agreement, Activaero will
grant Parion an exclusive, worldwide license to certain parts of its proprietary
FAVORITE inhalation approach including a unique, high efficiency aerosol
generator. Activaero's aerosol generator will be customized and integrated into
Parion's transnasal pulmonary aerosol delivery ("tPAD") system. The tPAD system
pairs the Activaero technology with Parion's proprietary therapeutic agents and
delivery device advancing the commercialization of combination products. In
return, Activaero will be eligible to receive an undisclosed upfront payment,
regulatory milestone payments and royalties.
Bernhard Müllinger, Chief Technical Officer of Activaero GmbH, commented:
"Currently, off-the-shelf inhalation devices carry significant disadvantages for
payers and patients. These devices force patients to inhale too fast resulting
in non-reproducible, inefficient inhalation maneuvers. Consequently, high
amounts of inhaled substance are deposited in the throat. These deposits are not
only wasted but also cause local irritations and side effects. With our FAVORITE
approach we can create safe and effective, pharmacoeconomically meaningful
aerosol-based therapies that are delivered into the lung with an unparalleled
consistency and lung deposition rates of more than 80%."
"The tPAD system's unique, slow aerosol infusion represents a paradigm shift in
nebulized delivery that aims to improve patients' quality of life in terms of
convenience, efficacy and tolerability." explains Paul Boucher, VP, Finance and
Business of Parion Sciences Inc. "We are delighted to partner with Activeaero's
expert team to integrate the proven, consistent and efficient aerosolization
capabilities of the FAVORITE approach to optimize the therapeutic potential of
the tPAD system."
About FAVORITE
FAVORITE is Activaero's proprietary, clinically and commercially proven
inhalation approach to effectively treat severe respiratory and pulmonary
diseases. FAVORITE actively regulates inspiration flow and inhalation volume. By
guiding, controlling and supporting the patient's breathing, optimal inhalation
patterns are created. Using FAVORITE, inhaled drugs can be selectively targeted
to pre-defined lung regions hence unlocking completely new opportunities for
novel aerosol therapies.
About Activaero
Activaero is a therapeutic area specialist developing new, pharmacoeconomically
meaningful treatment solutions for patients suffering from severe respiratory
diseases, including Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic
Fibrosis (CF), Idiopathic Pulmonary Fibrosis (IPF) and Pulmonary Hypertension.
Activaero was founded in 1998 in Germany and is a privately held company with
offices in Germany near Frankfurt and Munich as well as in Dublin, Ohio (USA).
www.activaero.de
About tPAD
The tPAD platform is designed to administer aerosolized medicines overnight via
transnasal application, shifting the patient's treatment burden away from day
time hours to periods during sleep. Its aerosol characteristics have been
optimized to efficiently deliver medication through a nasal cannula, bypassing
the nasal passages and depositing a high percentage into the lungs under natural
breathing.
About Parion
Based in Durham, NC, Parion Sciences is a privately-held, development-stage
pharmaceutical company that is leveraging its proprietary small molecule
chemistry and epithelial biology expertise to discover and develop an innovative
pipeline of therapies for diseases resulting from the failure of the body's
mucosal defenses, including chronic obstructive pulmonary disorder (COPD),
cystic fibrosis, bronchiectasis and dry eye disease. For more information,
please visit parion.com.
Contact us:
Activaero GmbH Media Contact
Christian Pangratz Anne Hennecke
Chief Business Officer MC Services AG
t: +49-89-897969-65 t: +49-89-210228-18
e: christian.pangratz@activaero.de e: anne.hennecke@mc-services.eu
www.activaero.de
Press release (PDF) :
http://hugin.info/156033/R/1753852/591674.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Activaero GmbH via GlobeNewswire
[HUG#1753852]
